Benign prostatic hyperplasia (BPH) is one of the most common and progressive diseases affecting aging men, and is histologically defined as an overgrowth of the epithelial and stromal cells of the transition zone and periurethral area. A variety of growth factors associated with epithelial/stromal interaction have been described in the pathophysiology of BPH; however, the cellular and molecular processes underlying the pathogenesis and development of BPH remain poorly understood. It has also been reported that intraprostatic inflammation frequently accompanies BPH, and accelerates the pathogenesis and progression of this condition. Acute intraprostatic inflammation causes symptoms that can be easily treated. However, many cases of chronic intraprostatic inflammation may go untreated because the condition has no symptoms and often goes undetected.

Enhancer of zeste homolog 2 (EZH2) is a known repressor of gene transcription. EZH2 is the catalytic subunit of polycomb repressive complex 2 that is a highly conserved histone methyltransferase targeting lysine-27 of histone H3. Several studies showed that EZH2 is commonly overexpressed in a wide variety of cancerous tissue types, including prostate and breast.
Although EZH2 is upregulated in advanced and metastatic prostate cancer, its role as a marker or driver of metastasis is yet to be resolved. A new hypothesis has emerged proposing that prostate cancer can be driven by prostate inflammation, which is supported by several epidemiological, histopathological, and molecular pathological studies. This is also partly supported by the fact that almost 20% of cancers are caused by chronic infections and/or inflammation. Interestingly, a recent study identified a new regulatory role for EZH2 in modulating the expression of several genes involved in immunoresponse and autocrine inflammation network. Suppression of EZH2 expression, by pharmacological inhibition or genetic deletion, resulted in the activation of these immunoresponse genes implicating EZH2 involvement in determining cancer immunity. Thus, we raised the question of whether EZH2 expression is modulated during prostatitis, and, if it is correlated with the expression of inflammatory cytokines like interleukin 6 (IL-6).

The aim of the current study was to evaluate the effect of prostate inflammation on the expression of EZH2. Thus, we measured the ribonucleic acid (RNA) expression of EZH2 in patients with BPH only and in BPH with prostatitis. We also investigated the association of EZH2 RNA expression with IL-6 serum levels and the histological types of prostatitis.

PATIENTS AND METHODS

Transrectal ultrasound (TRUS)-guided prostate biopsies were collected from 106 patients who were suspected of having prostate cancer, but the histology revealed BPH with or without prostatitis. All the men were of Middle Eastern origin. Ten to 12 core biopsies were taken from each patient using 18 fine gauge needles. The prostate tissue was obtained after written consent from each patient. The study was approved by the local ethics committee in compliance with the principles outlined in the Declaration of Helsinki.

Exclusion criteria included a history suggestive of ongoing urinary tract infection or acute prostatitis, the presence of an indwelling urethral catheter, and a history of previous prostate biopsy or previous urological procedures on the prostate gland. We also excluded cases where the histological examination revealed granulomatous prostatitis. We had 5 patients with this diagnosis (2 due to tuberculosis and 3 due to Schistosoma haematobium infections of the prostate). All 5 patients had very high prostate-specific antigen (PSA) serum levels (>50 ng/mL). Patients with percentage of free PSA <10% were excluded from the EZH2 gene expression analysis as they have a very high chance of having prostate cancer.

Tissue samples were fixed in 4% solution of formaldehyde (i.e., 10% formalin), then processed routinely into paraffin blocks, and the sections were then stained with hematoxylin and eosin stains. The extent of prostate inflammation was classified on the basis of the following criteria proposed by Anim et al. Briefly, (1) acute prostatitis (AP): focal glandular disruption with neutrophilic and macrophage cell reaction as well as accumulation in the gland lumen; (2) active chronic prostatitis (ACP): periglandular inflammatory infiltrate consisting predominantly of chronic inflammatory cells, but with some disruption of glandular epithelium as well as neutrophilic and macrophage infiltrate; and (3) chronic inactive prostatitis (CIP): periglandular fibrosis with surrounding chronic inflammatory infiltrate and/or lymphoid aggregate replacing a completely destroyed gland. BPH was diagnosed where there was a glandular and stromal hyperplasia with no significant inflammatory changes.

Serum Markers

IL-6 levels were measured using commercial enzyme-linked immunosorbent assay kits (GE Healthcare Life Sciences, Buckinghamshire, UK). The total PSA levels in blood serum were quantitatively measured by radioimmunoassay using Immunlite kits (DPC, Los Angeles California, United States). The serum-free PSA was determined, and the percentage of free PSA was calculated for all patients with total PSA values between 4 and 10 ng/mL. In patients where the PSA levels were greater than 10 ng/mL, but the histology did not show prostate cancer, follow-ups at 3 monthly intervals with PSA estimations were arranged. If PSA normalized within 3 months, the patients were included in the diagnosis of prostatitis. If PSA continued to rise, the patients were subjected to another round of TRUS-guided prostate biopsy to exclude prostate cancer. When three sets of biopsies failed to show cancer, the patients were classified as having chronic prostatitis and followed up at 6 month-interval.

Ribonucleic acid isolation, reverse transcription, and quantitative real-time polymerase chain reaction

Of the 10 to 12 core biopsies taken per patient, a representative core biopsy specimen was selected for EZH2 RNA isolation. Either ends of the selected core biopsy specimens were sent for histological analysis, and the central piece of the core was used for EZH2A isolation. Total RNA was purified using TRIzol reagent (Invitrogen, Carlsbad, California, United States) following the manufacturer’s instructions. RNA concen-
Enhancer of zeste homolog 2 expression in prostatic diseases

**Table 1.** Descriptive statistics of variables in benign prostatic hyperplasia (BPH) only and benign prostatic hyperplasia with prostatitis patients.

| Characteristic          | BPH with prostatitis (n=56) | BPH (n=50) | P  |
|-------------------------|-----------------------------|------------|----|
| Age, year               |                             |            | .11|
| Median                  | 67                          | 62         |    |
| Range                   | 47-84                       | 42-79      |    |
| PSA, ng/mL              |                             |            |    |
| Median                  | 11.75                       | 5.9        | <.0001|
| Range                   | 0.75-68.7                   | 0.1-26     |    |
| Serum IL-6, pg/mL       |                             |            |    |
| Median                  | 6.07                        | 4.1        | <.0001|
| Range                   | 2.48                        | 1.1-6.6    |    |
| Histological types of prostatitis | n=56 (%)     |            |    |
| Acute prostatitis       | 12 (21.4)                   |            |    |
| Chronic active prostatitis | 32 (57.1)   |            |    |
| Chronic active prostatitis | 12 (21.4)   |            |    |
| *Mann-Whitney U test    |                             |            |    |

BPH: Benign prostatic hyperplasia; IL-6: interleukin 6; PSA: prostate-specific antigen.

Since the distribution of EZH2 expression in BPH and BPH with prostatitis patients was not Gaussian, the differences among two groups were assessed by the nonparametric Mann-Whitney U test. Any possible correlations between EZH2 expression and other continuous variables were assessed by the Spearman correlation coefficient (r). We used univariate and multivariate unconditional logistic regression analysis to study the ability of the variables to predict the presence of prostatitis. The relationship between EZH2 mRNA expression and types of histological prostatitis was determined using chi-square and Fisher exact test where appropriate. A P value <.05 was considered statistically significant.

**RESULTS**

The clinical and pathological data of the patients investigated in this study are listed in **Table 1**. Based on histological analysis, the patient population was classified into the following categories: BPH only (n=50) and BPH with prostatitis (n=56). The BPH with prostatitis patients were further divided into the following groups: AP (n=12), ACP (n=32) and CIP (n=12). High levels of total PSA were detected in our patient cohort as compared with whites in the United States and Europe. This finding was previously reported for men of Middle Eastern origin; however, no clear reason was reported for these high PSA levels in BPH and BPH with prostatitis conditions in these men.16

**Correlation between enhancer of zeste homolog 2 messenger ribonucleic acid expression and other variables in benign prostatic hyperplasia with prostatitis**

In BPH with prostatitis, we found a statistically significant negative correlation between EZH2 expression and serum IL-6 levels using these parameters as continuous variables ($r_s = -0.31, P = .02$) (**Figure 2**).
significant correlation between \(\text{EZH2} \) expression and patient age (\( r_s = -0.099, P = .466 \)) and PSA levels (\( r_s = 0.18, P = .184 \)) was not observed. The data were then analyzed using a univariate logistic regression model to investigate whether \(\text{EZH2} \) mRNA expression levels are associated with conditions of BPH with prostatitis (\( \text{Table 3} \)). High levels of \(\text{EZH2} \) expression were found to be associated with an increased risk of having BPH with prostatitis (crude odds ratio 0.20, 95% CI 0.06-0.65, \( P = .0076 \)). Similarly, total serum PSA levels proved to be an important parameter for distinguishing simple BPH from BPH with prostatitis (crude odds ratio 0.19, 95% CI 0.06-0.56, \( P = .0028 \)). Furthermore, the multivariate analysis showed that \(\text{EZH2} \) mRNA expression was an independent predictor of the development of BPH with prostatitis with crude odds ratio of 0.02 (95% CI 0.003-0.92, \( P = .044 \)), improving the diagnostic significance of PSA.

**DISCUSSION**

\(\text{EZH2} \) is a polycomb group protein that acts as a transcriptional repressor controlling cellular memory and helps in maintaining cell type identity.\(^{17}\) Thus, deregulation of its expression and subsequently that of the transcriptional machinery can result in cell identity loss and oncogenic transformation. Upregulation of its gene expression has been linked to cell growth promotion and prostate cancer aggressiveness.\(^7\) In breast cancer, down regulation of \(\text{EZH2} \) expression, chemically or genetically, caused reactivation of 58 \(\text{EZH2} \)- repressed immune response genes like interleukin 8 (IL-8), tumor necrosis factor (TNF), chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-X-C motif) ligand 2 (CXCL2), and many others.\(^{14}\) Our study showed that although \(\text{EZH2} \) expression is detected in both types of BPH, overexpression of \(\text{EZH2} \) mRNA in BPH with acute or chronic active prostatitis was more frequent than in BPH only conditions (\( P < .0001 \)). The logistic regression analysis showed that \(\text{EZH2} \) may be an independent factor in the discrimination of the two prostatic conditions. This is further supported by the parallel increase in PSA levels in BPH with the prostatitis group, and the additive effect of \(\text{EZH2} \) to the predictive power of the multivariate model, despite the lack of correlation between the two factors (\( r_s = 0.18, P = .184 \)). We also investigated the relationship of \(\text{EZH2} \) expression positivity with the different types of histological prostatitis (\( \text{Table 4} \)). \(\text{EZH2} \) expression had a remarkable low de-
Table 2. Relative EZH2 mRNA expression in benign prostatic hyperplasia (n=50) and benign prostatic hyperplasia with prostatitis (n=56) patients.

| Pathological specimen            | Mean (SE) | Median | Range      | P*    |
|----------------------------------|-----------|--------|------------|-------|
| Benign prostatic hyperplasia     | 1.3 (0.13)| 1.2    | 0.03-3.9   |       |
| Benign prostatic hyperplasia with prostatitis | 5.7 (0.58)| 4.58   | 0.51-17.58 | <.0001|
| Acute prostatitis                | 1.1 (0.22)| 0.9    | 0.19-2.6   | <.0001|
| Chronic active prostatitis       | 7.6 (0.74)| 8      | 1.1-18     | .0001 |
| Chronic inactive prostatitis     | 3.6 (0.5 )| 3.4    | 1.1-7      | .413  |

EZH2: enhancer of zeste homolog 2; mRN: messenger ribonucleic acid; SE: standard error.

*Mann-Whitney U test: Comparison between EZH2 mRNA expression in the different types of prostatitis versus benign prostatic hyperplasia only samples.

Table 3. Logistic regression analysis for predicting the presence of benign prostatic hyperplasia with prostatitis.

| Covariant            | Crude odds ratio | 95% CI      | P   |
|----------------------|------------------|-------------|-----|
| Univariate analysis  |                  |             |     |
| EZH2                 | 0.20             | 0.06-0.65   | .0076|
| PSA                  | 0.19             | 0.06-0.56   | .0028|
| Multivariate analysis|                  |             |     |
|                       | 0.05             | 0.003-0.92  | .044 |

EZH2: enhancer of zeste homolog 2; PSA: prostate-specific antigen.

Table 4. Relationship between EZH2, mRNA expression, benign prostatic hyperplasia, and different types of prostatitis.

| Pathology of specimen | No. specimen | Number expressing EZH2 (%) | P*   |
|-----------------------|--------------|-----------------------------|------|
| Total                 | 106          |                             |      |
| Benign prostatic hyperplasia | 50          | 36 (72)                      |      |
| Benign prostatic hyperplasia with prostatitis | 56          | 52 (92.8)                    | .008 |
| Acute prostatitis     | 12           | 12 (100)                     | .05  |
| Chronic active prostatitis | 32          | 32 (100)                     | .0006|
| Chronic inactive prostatitis | 12          | 8 (66.7)                     | .73  |

EZH2: enhancer of zeste homolog 2; mRNA: messenger ribonucleic acid.

*Fisher exact test: Comparison between EZH2 mRNA expressions in the different types of prostatitis versus benign prostatic hyperplasia only samples. Chi square test ($\chi^2=16$, P=.0014) was used to compare the expression of EZH2 across the different types of benign prostatic hyperplasia with prostatitis with that of benign prostatic hyperplasia only.

It is commonly known that inflammatory cascades are crucial in the development of simple BPH; however, the primary event in the activation of this cascade is still unclear. The importance of these inflammatory reactions in the pathogenesis of BPH symptoms were confirmed by the positive correlation between the young-onset prostatitis and later development of lower urinary tract symptoms. IL-6 is a cytokine expressed in the stromal and luminal epithelial BPH cells, and characterized by its proliferative action, which suggests its role during the IL-17-dependent BPH-associated inflammatory processes. We report elevated serum levels of IL-6 in BPH with prostatitis patients, as compared to BPH only. A strong negative correlation was also reported between IL-6 and EZH2 levels in BPH with prostatitis (P=.011), reinforcing the potential novel role of EZH2 in suppressing the expression of some immune response genes. Several studies have reported on the expression pattern of many cytokines and shed a light on their role in prostate tissue inflammation. IL-8 is a direct mediator of neutrophil accumulation and activation at inflammatory sites. IL-15 plays an important role in the generation and maintenance of intraprostatic infiltrates. IL-17 is the principal player in the pathogenesis and maintenance of the immune responses because of its role in the activation of the proinflammatory network. Thus, it is not surprising that a cytokine-like IL-6 is overexpressed in BPH with prostatitis conditions and...
found to be inversely correlated with the new regulatory role of EZH2.

The probable use of EZH2 expression may be used in deciding which patients may develop prostate cancer in the future by checking for the presence of its overexpression. In this study, 5 patients with high grade prostatic intraepithelial neoplasia (HGPIN) in addition to BPH + chronic prostatitis had higher levels of expression of EZH2 compared to those without HGPIN or those with BPH. Furthermore, patients with prostate cancer had the highest expression levels of EZH2 compared to patients with BPH only, BPH + prostatitis, or BPH + prostatitis + high-grade prostatic intraepithelial neoplasia. From basic principles, it would appear that patients with high PSA and overexpression of EZH2 may subsequently develop prostate cancer. Unfortunately, our follow-up period was just about 4 years and no such cases were documented by us. It could be argued that such patients require a closer follow-up and repeat prostate biopsy.

Our data shows that EZH2 mRNA expression is positively associated with prostatitis conditions associated with BPH. Also, its inverse correlation with serum IL-6 expression supports the new proposed regulatory role of EZH2. Future studies should aim at the evaluation of EZH2 protein concentrations in BPH and prostatitis prostate tissues using immunohistochemistry and immunochemical assays. Our findings would be certainly strengthened if other inflammatory factors (cytokines and chemokines) were tested for their expression, including IL-8, IL-15, IL-17, and TNF and their relationships with EZH2 expression levels in such inflammatory conditions of the prostate are explored.

Acknowledgments
This work was supported by Kuwait University Research Grant MS01/05. The authors would like to thank the following: Ms. Reeba M. Eapin, Dr. Asa Prasad, and Ms. Jetha S. Jones for their technical support.
REFERENCES

1. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int J Cell Biol 2000;199:65-116.
2. Roehrborn CG, Kaplan SA, Noble WD, Lucia MS, Slawin KM, McVary KT, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol 2005;173:346.
3. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007;100:237-31.
4. Koff A, Koseoglu H, Celebi I, Yorukoglu K, Eisen A. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 2008;40:155-60.
5. Tuncel A, Uzun B, Eryar T, Karabulut E, Seckin S, Atan A. Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention?. Eur Urol 2005;48:277-83.
6. Ha JY, Kwak DY, Chang HS, Park CH, Kwon SY, Kim CI. Relationship between acute urinary retention and intraprostatic inflammation in benign prostatic hyperplasia. Korean J Urol 2008;49:1081-6.
7. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
8. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11.
9. Varambally S, Dhanasekaran SM, Zhou M, Barrett TR, Kumar-Sinha C, Sanda MB, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
10. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?. Cancer Cell 2002;2:349-50.
11. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
13. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81.
14. Sun F, Chan E, Wu, Z, Yang X, Marquez VE, Yu Q. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 2009;8:3191-202.
15. Anim JT, Kehinde EO, Prasad A, Sheikh M, Mojmiminyi OA, Ali Y, et al. Relationship between serum prostate-specific antigen and the pattern of inflammation in both benign and malignant prostate disease in Middle Eastern men. Int Urol Nephrol 2006;38:27-32.
16. Kehinde EO, Sheikh M, Mojmiminyi OA, Francis I, Anim JT, Nkansa-Dwamena D, et al. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: The clinician’s dilemma. BJU Int 2003;91:618-22.
17. Laibl G, Wolf A, Dom R, Reuter G, Nislow C, Lebersanger A, et al. Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997;16:3219-32.
18. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-88.
19. Sutcliffe S, Giovannucci E, De Marzo AM, William VC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005;162:998-1006.
20. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001;168:447-54.
21. Baggioili M, Loetscher P, Moser M. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995;17;103-8.
22. Liu L, Li Q, Han R, Li X, Zeng H, Zhu Y, et al. Evaluation of interleukin-8 in expressed prostatic secretions as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009;74:340-4.
23. Wilkinson PC, Liew FY. Chemoattraction of human T lymphocytes by interleukin-15. J Exp Med 1995;181:1255-9.
24. Steiner GE, Stix U, Handisurya A, Wilhelm M, Hautel A, Redmayn F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostate tissue. Lab Invest 2003;83:1131-46.
25. König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostatic hyperplasia and prostate cancer. Prostate 2004;58:121-9.
26. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.